AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00024102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
Study NCT00890214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prostacyclin
Description: prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
Study NCT00890214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
Study NCT02894359 — intervention group
Intervention type: DEVICE
Intervention: cone beam imagery of cervical spine
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will continue on their stable, pre-screening metformin daily dose of >= 1500 mg for at least 12 weeks prior to randomization and during the study
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue on their stable, pre-screening metformin daily dose of >= 1500 mg for at least 12 weeks prior to randomization and during the study
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
Study NCT01678820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
Study NCT03051022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg
Description: Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
Study NCT03051022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 2 mg
Description: Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
Study NCT02773680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical impedance tomography
Description: One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
Study NCT01751230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIC E-Moms
Description: Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
Study NCT04199312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The MMS device will be used to perform the treatments.
Study NCT02970513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric evaluation
Description: The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
Study NCT02314988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL.
Study NCT02314988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline.
Study NCT02086162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based motivational decision support system
Study NCT02086162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Education
Study NCT01737996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 + faldaprevir
Description: fixed dose combination
Study NCT01463592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENESSANS , INTERFERON ALPHA 2b, Ribavirin
Description: ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
Study NCT01463592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2b AND RIBAVIRIN
Description: INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
Study NCT01463592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RENESSANS
Description: ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
Study NCT00792688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Gel (0.1%)
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Study NCT00792688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Gel (1.0%)
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Study NCT00792688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLYC-101 Placebo
Description: Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
Study NCT02225366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LL37
Description: Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
Study NCT02225366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photographs
Description: Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
Study NCT02042326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
Study NCT01106677 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
Study NCT01106677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
Study NCT01106677 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
Study NCT01106677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
Study NCT01106677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin immediate release
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
Study NCT01106677 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin immediate release
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
Study NCT01106677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin immediate release
Description: The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
Study NCT01326468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
Study NCT01326468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy.
Study NCT01326468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
Study NCT01326468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
Study NCT04112602 — intervention group
Intervention type: OTHER
Intervention: Sputum
Description: Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.
Study NCT04112602 — intervention group
Intervention type: OTHER
Intervention: Tracheal aspiration
Description: Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
Study NCT00623935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (40 mg/m2/day x 4 days)
Study NCT00623935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
Study NCT00623935 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
Study NCT00623935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Allogeneic stem cell transplant from related or unrelated donor
Study NCT03178240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: photoaging mirroring intervention
Description: selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
Study NCT02828124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986183
Description: specified dose on specified days
Study NCT02828124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: specified dose on specified days
Study NCT02770404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin
Description: 100, 200, or 400 mg of nafithromycin
Study NCT02770404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV matching placebo
Study NCT03932175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Behaviorial intervention on non-invasive ventilation use and adherence alongside lifestyle changes recommendations supported by an mHealth tool (MyPathway app)
Study NCT03790228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Combined With Pemetrexed And Carboplatin
Description: Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
Study NCT00286780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: 80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
Study NCT03788434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VE303
Description: VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.
Study NCT03788434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
Study NCT05043597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Thrombus aspiration
Study NCT01151202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG NPP709syrup
Study NCT01151202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG NPP709syrup
Study NCT02847494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: metoclopramide 10mg intravenous infusion over 15 minutes
Study NCT02847494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 10mg intramuscular injection
Study NCT02847494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone acetate
Description: methylprednislone acetate 160mg intramuscular injection
Study NCT03349268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed xenon ultraviolet (PX-UV) Device
Description: Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2.
Study NCT03349268 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsed xenon ultraviolet (PX-UV) Device
Description: Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2.
Study NCT03349268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Device
Description: Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2.
Study NCT03349268 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2.
Study NCT01706419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified rice cold extruded kernel
Study NCT01706419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified rice warm extruded kernel
Study NCT01706419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortiified rice hot extruded kernel
Study NCT03326947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin and 5-fluorouracil
Description: Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy
Study NCT04187820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
Study NCT00114634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg yolk preparation with cholesterol
Description: Egg yolk preparation with cholesterol
Study NCT00114634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg substitute, without cholesterol
Description: Placebo control. Egg substitute, without cholesterol
Study NCT00877903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal®
Description: Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
Study NCT00877903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of excipients of Prochymal®
Study NCT03283696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV
Study NCT03283696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV
Study NCT03283696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Administered IV
Study NCT03283696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Administered per standard of care
Study NCT03788005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization
Description: Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
Study NCT04530357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QazCovid-in® - COVID-19 inactivated vaccine
Description: QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
Study NCT01544309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society \[JAS\] Guidelines \[GL\] after 3 months, had the atorvastatin \[ATV\] dose of 20 mg.)